Informação sobre produto
- Benzamide, N-(cyanomethyl)-4-[2-[[4-(4-morpholinyl)phenyl]amino]-4-pyrimidinyl]-, methanesulfonate (1:?)
Momelotinib mesylate is a potent, selective inhibitor of PD-L1. It has been shown to inhibit the expression of PD-L1 in vitro and in vivo. Momelotinib mesylate binds to the B7-H1 protein found on cells that line blood vessels, which is a protein target for tumor cells. It also inhibits the proliferation of cancer cells and may lead to their death. Momelotinib mesylate has been approved by the FDA as a treatment method for patients with myelofibrosis who have had no success with other treatments. This drug is given orally and can be used together with other medications such as steroids or erythropoietin. It has been shown to reduce organ damage and improve quality of life in these patients.
Propriedades químicas
Consulta técnica sobre: 3D-GSB63607 Momelotinib mesylate
Se desejar solicitar um orçamento ou fazer uma encomenda, por favor, adicione os produtos ao seu carrinho e depois solicite um orçamento ou encomenda a partir do carrinho. É mais rápido, mais barato e poderá beneficiar-se dos descontos e outras vantagens disponíveis.
